Molecular Profiling in the Diagnosis of Gliomas

Molecular Profiling in the Diagnosis of Gliomas

In this presentation, pathologist Maria Martinez­-Lage, MD, offers a profile of the four subtypes of glioblastoma as identified by gene expression analysis and molecular signatures, as well as their respective genomic alterations, prognoses and signaling pathways, and discusses the approach of the new WHO classification of glioblastoma and current efforts at the Penn Center for Personalized Diagnosis to expand the panel of known gene mutations for the disease.

Director of the Penn Brain Tumor Center Steven Brem, MD, considers the new paradigm for safe maximal (supratotal) resection of glioblastoma in light of recent advances in brain mapping and tractography.

Tara Gangadhar, MD, examines three recent clinical trials from ASCO 2017 that reported the use of targeted immunotherapy to gain durable partial or complete responses in patients with melanoma metastatic to the brain

Chief of the Division of Thoracic Surgery at Penn Medicine John C Kucharczuk, MD, discusses recent advances in surgical practice for lung cancer and the critical value of lung cancer screening for patients at risk.

Stephen J. Schuster, MD, Director of the Lymphoma Program at the Abramson Cancer Center of the University of Pennsylvania, reviews the highlights from B cell lymphoma clinical trials presented at ASH 2015.

Steven Brem, MD, reviews Novo-TTF (tumor-treating fields), a modality for glioblastoma that involves the induction of a low intensity electric field within the brain to disrupt cell division during mitosis.

Christos Davatzikos, PhD, Director of the Center for Biomedical Image Computing and Analytics at Penn Medicine, examines computational neuro-oncology and its application to prognosis and treatment of brain tumors.

David A. Mankoff, MD, PhD, reviews the methods to determine the maximal tolerated dose of I-131 for the treatment of patients with advanced thyroid cancer and the characteristics of radioiodine-refractory disease in this population.

In this video, Carl June, MD, reflects on the case of Emily Whitehead, the first pediatric patient treated with CAR T cell therapy for pediatric relapsed, refractory ALL --and her four years in complete remission.

Precision Medicine ­ Treating the right patient, at the right time, with the right treatment. David B. Roth, MD, PhD, Chair, Department of Pathology and Laboratory Medicine and Director of the Precision Medicine Program, discusses the ...

In this video, Jason Moore, PhD, outlines the role of bioinformatics as a component of precision medicine and its valuable part in the diagnosis and treatment choices for patients with serious disease.

Noelle Frey, MD, a hematologist-oncologist at Penn Medicine and the Abramson Cancer Center, presents a summary of approaches to the myelodysplastic syndromes with a focus upon improved prognosis and the application of novel drug therapies.

Director of the Leukemia Program at the Abramson Cancer Center and Penn Medicine, Selina Luger, MD, presents an overview of the past and current state of therapy for the leukemias and the improving prognosis for patients with the disease.

James K Mangan, MD, PhD, discusses investigational approaches to the treatment of acute leukemia and provides a review of standards for AML and ALL, as well as such novel therapies as the TKIs FLT3-ITD and dasantinib, gemtuzumab, CTL-019 and blinatumomab.

David L. Porter, MD discusses the treatment algorithims in use at Penn Medicine and the Abramson Cancer Center to minimize the effects of graft-versus-host disease, one of the severe and debilitating effects of chemotherapy in patients ...

Hematologist-Oncologist David L. Porter, MD, presents on the pioneering use of CTL-019 (formerly CART-19) at Penn Medicine for adoptive immunotherapy in patients with relapsed or chemotherapy-refractory chronic lymphocytic leukemias (CLL).

Oncologist Jakub Svoboda, MD, offers an overview of recent advances in the treatment of Hodgkin Lymphoma, including new biological and targeted agents, optimal combinations and the evolving concept of limiting therapy.

In this video, Roger B. Cohen, MD, considers the challenge inherent in the vast amount of data arising from genomic testing from the perspective of a practicing oncologist, and how the profession might put this data to its best use in the future.

In this summary, Robert H. Vonderheide, MD, DPhil, offers an overview of recent advances at Penn Medicine in immunological therapy for pancreatic cancer based upon antibodies that activate the patient's immune system

Gynecological Oncologist Janos Tanyi, MD, discusses his philosophy of care for patients with gynecological cancers, and reviews the comprehensive array of treatments for these malignancies at Penn Medicine.